246 related articles for article (PubMed ID: 23796897)
1. A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival.
Zheng S; Fu J; Vegesna R; Mao Y; Heathcock LE; Torres-Garcia W; Ezhilarasan R; Wang S; McKenna A; Chin L; Brennan CW; Yung WK; Weinstein JN; Aldape KD; Sulman EP; Chen K; Koul D; Verhaak RG
Genes Dev; 2013 Jul; 27(13):1462-72. PubMed ID: 23796897
[TBL] [Abstract][Full Text] [Related]
2. Detection of recurrent rearrangement breakpoints from copy number data.
Ritz A; Paris PL; Ittmann MM; Collins C; Raphael BJ
BMC Bioinformatics; 2011 Apr; 12():114. PubMed ID: 21510904
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel candidate target genes in amplicons of Glioblastoma multiforme tumors detected by expression and CGH microarray profiling.
Ruano Y; Mollejo M; Ribalta T; Fiaño C; Camacho FI; Gómez E; de Lope AR; Hernández-Moneo JL; Martínez P; Meléndez B
Mol Cancer; 2006 Sep; 5():39. PubMed ID: 17002787
[TBL] [Abstract][Full Text] [Related]
4. Identification of Recurrent Chromosome Breaks Underlying Structural Rearrangements in Mammary Cancer Cell Lines.
Senter NC; McCulley A; Kuznetsov VA; Feng W
Genes (Basel); 2022 Jul; 13(7):. PubMed ID: 35886011
[TBL] [Abstract][Full Text] [Related]
5. GSVD comparison of patient-matched normal and tumor aCGH profiles reveals global copy-number alterations predicting glioblastoma multiforme survival.
Lee CH; Alpert BO; Sankaranarayanan P; Alter O
PLoS One; 2012; 7(1):e30098. PubMed ID: 22291905
[TBL] [Abstract][Full Text] [Related]
6. Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data.
Shah N; Lankerovich M; Lee H; Yoon JG; Schroeder B; Foltz G
BMC Genomics; 2013 Nov; 14(1):818. PubMed ID: 24261984
[TBL] [Abstract][Full Text] [Related]
7. An integrative characterization of recurrent molecular aberrations in glioblastoma genomes.
Sintupisut N; Liu PL; Yeang CH
Nucleic Acids Res; 2013 Oct; 41(19):8803-21. PubMed ID: 23907387
[TBL] [Abstract][Full Text] [Related]
8. The use of ultra-dense array CGH analysis for the discovery of micro-copy number alterations and gene fusions in the cancer genome.
Przybytkowski E; Ferrario C; Basik M
BMC Med Genomics; 2011 Jan; 4():16. PubMed ID: 21272361
[TBL] [Abstract][Full Text] [Related]
9. Analysis of a breakpoint cluster reveals insight into the mechanism of intrachromosomal amplification in a lymphoid malignancy.
Sinclair PB; Parker H; An Q; Rand V; Ensor H; Harrison CJ; Strefford JC
Hum Mol Genet; 2011 Jul; 20(13):2591-602. PubMed ID: 21487021
[TBL] [Abstract][Full Text] [Related]
10. High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray.
Yin D; Ogawa S; Kawamata N; Tunici P; Finocchiaro G; Eoli M; Ruckert C; Huynh T; Liu G; Kato M; Sanada M; Jauch A; Dugas M; Black KL; Koeffler HP
Mol Cancer Res; 2009 May; 7(5):665-77. PubMed ID: 19435819
[TBL] [Abstract][Full Text] [Related]
11. The prognostic role of intragenic copy number breakpoints and identification of novel fusion genes in paediatric high grade glioma.
Carvalho D; Mackay A; Bjerke L; Grundy RG; Lopes C; Reis RM; Jones C
Acta Neuropathol Commun; 2014 Feb; 2():23. PubMed ID: 24548782
[TBL] [Abstract][Full Text] [Related]
12. Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes.
Duncan CG; Killela PJ; Payne CA; Lampson B; Chen WC; Liu J; Solomon D; Waldman T; Towers AJ; Gregory SG; McDonald KL; McLendon RE; Bigner DD; Yan H
Oncotarget; 2010 Aug; 1(4):265-77. PubMed ID: 21113414
[TBL] [Abstract][Full Text] [Related]
13. MTBP regulates cell survival and therapeutic sensitivity in TP53 wildtype glioblastomas.
Song Y; Zhang L; Jiang Y; Hu T; Zhang D; Qiao Q; Wang R; Wang M; Han S
Theranostics; 2019; 9(20):6019-6030. PubMed ID: 31534534
[No Abstract] [Full Text] [Related]
14. MDM2 and CDK4 amplifications are rare events in salivary duct carcinomas.
Grünewald I; Trautmann M; Busch A; Bauer L; Huss S; Schweinshaupt P; Vollbrecht C; Odenthal M; Quaas A; Büttner R; Meyer MF; Beutner D; Hüttenbrink KB; Wardelmann E; Stenner M; Hartmann W
Oncotarget; 2016 Nov; 7(46):75261-75272. PubMed ID: 27662657
[TBL] [Abstract][Full Text] [Related]
15. A survey of glioblastoma genomic amplifications and deletions.
Rao SK; Edwards J; Joshi AD; Siu IM; Riggins GJ
J Neurooncol; 2010 Jan; 96(2):169-79. PubMed ID: 19609742
[TBL] [Abstract][Full Text] [Related]
16. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.
Moulton T; Samara G; Chung WY; Yuan L; Desai R; Sisti M; Bruce J; Tycko B
Am J Pathol; 1995 Mar; 146(3):613-9. PubMed ID: 7887443
[TBL] [Abstract][Full Text] [Related]
17. Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis.
Lou J; Hao Y; Lin K; Lyu Y; Chen M; Wang H; Zou D; Jiang X; Wang R; Jin D; Lam EW; Shao S; Liu Q; Yan J; Wang X; Chen P; Zhang B; Jin B
Mol Cancer; 2020 Sep; 19(1):138. PubMed ID: 32894144
[TBL] [Abstract][Full Text] [Related]
18. Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma.
Park AK; Kim P; Ballester LY; Esquenazi Y; Zhao Z
Neuro Oncol; 2019 Jan; 21(1):59-70. PubMed ID: 30053126
[TBL] [Abstract][Full Text] [Related]
19. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
Cen L; Carlson BL; Schroeder MA; Ostrem JL; Kitange GJ; Mladek AC; Fink SR; Decker PA; Wu W; Kim JS; Waldman T; Jenkins RB; Sarkaria JN
Neuro Oncol; 2012 Jul; 14(7):870-81. PubMed ID: 22711607
[TBL] [Abstract][Full Text] [Related]
20. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration.
Ruano Y; Ribalta T; de Lope AR; Campos-Martín Y; Fiaño C; Pérez-Magán E; Hernández-Moneo JL; Mollejo M; Meléndez B
Am J Clin Pathol; 2009 Feb; 131(2):257-63. PubMed ID: 19141386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
